Product Description
Risperidone (Risperdal), a psychotropic atypical antipsychotic agent, is thought to act via dopamine D(2) and serotonin (5-HT [5-hydroxytryptamine])(2A) receptor antagonism. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/17927305/)
Mechanisms of Action: D2 Inhibitor,5-HT2A Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Bipolar Disorder | Autism Spectrum Disorder | Schizophrenia | Autism Spectrum Disorder | Tic Disorders | Schizophrenia | Schizophrenia
Known Adverse Events: Abdominal Pain | Dizziness | Dystonia | Pain Unspecified | Tremor | Nasopharyngitis | Pharyngitis | Respiratory Tract Infections | Constipation | Diarrhea | Dyspepsia | Musculoskeletal Pain
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Jordan, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Affective Disorders, Psychotic|Atrial Fibrillation|Psychotic Disorders|Schizophrenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| QUARTZ | P1 |
Recruiting |
Schizophrenia |
2026-05-01 |
|
| LYN 005-C-301 | P3 |
Completed |
Affective Disorders, Psychotic|Schizophrenia|Psychotic Disorders |
2023-11-03 |
|
| DLP-114 | P2 |
Completed |
Schizophrenia |
2023-02-10 |
32% |
| ACTRN12619000658112 | P3 |
Not yet recruiting |
Atrial Fibrillation |
2020-06-01 |